No attachments available.
TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Contact and place of performance
Caleb Ledgerwood
Los Alamos, NM 87545
USA
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value market...
View moreHow it Works:
The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies.
Key Advantages:
Market Applications:
Development Status: TRL 2
US patent pending
LA-UR-26-22810
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
m.lanl.gov/tech-search
The Department of Energy contractor, Triad National Security, LLC, identifies a technology licensing opportunity for the Clathrate Therapeutics Platform developed at Los Alamos National Laboratory. This novel platform enables the controlled, localized delivery of therapeutic gases to treat diseases such as cancer, cardiovascular conditions, and neurological disorders. By stabilizing gases within a biocompatible structure for gradual release under physiological conditions, the technology minimizes systemic exposure and addresses traditional safety and dosing limitations. The platform is supported by integrated computational modeling to optimize treatment parameters and is currently at Technology Readiness Level (TRL) 2 with a U.S. patent pending under identifier LA-UR-26-22810.
The opportunity is categorized under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals. There is no set-aside designated for this notice. The technology is positioned for commercialization in the oncology, regenerative medicine, and medical device sectors, specifically for firms interested in drug-device combinations or computational drug development. Los Alamos National Laboratory offers this invention for exclusive or non-exclusive licensing to both established and start-up companies to transition the research into commercial innovations.
Caleb Ledgerwood serves as the primary point of contact for this special notice, which has a response deadline of December 4, 2026. The place of performance is located in Los Alamos, New Mexico. Interested parties may engage with the laboratory to discuss licensing agreements, though this notice does not constitute a request for external development services. Metadata indicates there are no attachments associated with this solicitation, which was published on June 4, 2026, under solicitation number S-195396.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.